Accession Therapeutics
2 known investors
Find your way into Accession Therapeutics
209 people in our graph share verified history with the Accession Therapeutics team — schools, employers, funds. One of them is your warm intro.
Andrew McLoughlinunlockedknows Alan Parker · together at The University of Sheffield (overlapped)
×10knows the team · via The University of Sheffield
knows the team · via 7 yrs 4 mos
Accession Therapeutics develops cancer treatments by harnessing immune system mechanisms, with a focus on T cell receptor therapies and engineered cell therapies. The company is led by experienced biotech entrepreneurs and scientific experts with a track record in bringing immunological oncology projects to clinical development.
Founders & leadership
AP
Alan ParkerinCSO and Founder of TroceptAlan Parker holds a PhD in Gene Therapy from the University of Birmingham and an undergraduate degree in Genetics from the University of Sheffield. He is CSO of Trocept Therapeutics (part of Accession Therapeutics) and leads a research group at Cardiff University's School of Medicine developing virotherapies for cancer, with expertise in immuno-oncology and translational oncology supported by multiple grants from Cancer Research UK, charities, and UK research councils.
BJ
Bent JakobseninCEO and Founder
Investors · 2
In the news
Frequently asked questions
- What does Accession Therapeutics do?
- Accession Therapeutics develops cancer treatments by harnessing immune system mechanisms, with a focus on T cell receptor therapies and engineered cell therapies. The company is led by experienced biotech entrepreneurs and scientific experts with a track record in bringing immunological oncology projects to clinical development.
- Who founded Accession Therapeutics?
- Accession Therapeutics was founded by Alan Parker.
- Who are Accession Therapeutics's investors?
- Accession Therapeutics's investors include iGlobe Partners, Birk Venture.